Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Stoter

Showing results (111-120 of 249) with videos related to

Pageof 25
Sort By:
Cancer Chemotherapy and Pharmacology|March 6, 1998
Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitroJ Ma, M Maliepaard, K Nooter, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 1995
Phase I study of weekly high-dose cisplatin combined with long-term oral etoposide in advanced solid tumorsA S Planting, M E van der Burg, M de Boer-Dennert, et al.
British Journal of Cancer|May 1, 1994
Pharmacokinetic-dynamic relationship of cisplatin in vitro: simulation of an i.v. bolus and 3 h and 20 h infusionJ Ma, J Verweij, H J Kolker, et al.
British Journal of Cancer|October 1, 1993
Phase I/II study of a short course of weekly cisplatin in patients with advanced solid tumoursA S Planting, M E van der Burg, M de Boer-Dennert, et al.
British Journal of Cancer|November 17, 2001
Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapyR de Wit, A C de Boer, G H vd Linden, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 26, 1999
Disposition of [G-(3)H]paclitaxel and cremophor EL in a patient with severely impaired renal functionH Gelderblom, J Verweij, E Brouwer, et al.
International Journal of Cancer|January 17, 1996
Modulation of immune parameters in patients with metastatic renal-cell cancer receiving combination immunotherapy (IL-2, IFN alpha and autologous IL-2-activated lymphocytes)J W Gratama, P I Schmitz, S H Goey, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|January 1, 1994
Utility assessment in cancer patients: adjustment of time tradeoff scores for the utility of life years and comparison with standard gamble scoresA M Stiggelbout, G M Kiebert, J Kievit, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1991
Phase I study of DABIS maleate given once every 3 weeksM E van der Burg, A S Planting, G Stoter, et al.
International Journal of Radiation Oncology, Biology, Physics|June 2, 1998
Expression of p53, p21/WAF/CIP, Bcl-2, Bax, Bcl-x, and Bak in radiation-induced apoptosis in testicular germ cell tumor linesH Burger, K Nooter, A W Boersma, et al.
Pageof 25

Showing results (111-120 of 249) with videos related to

Sort By:
Pageof 25
Cancer Chemotherapy and Pharmacology|March 6, 1998
Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitroJ Ma, M Maliepaard, K Nooter, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 1995
Phase I study of weekly high-dose cisplatin combined with long-term oral etoposide in advanced solid tumorsA S Planting, M E van der Burg, M de Boer-Dennert, et al.
British Journal of Cancer|May 1, 1994
Pharmacokinetic-dynamic relationship of cisplatin in vitro: simulation of an i.v. bolus and 3 h and 20 h infusionJ Ma, J Verweij, H J Kolker, et al.
British Journal of Cancer|October 1, 1993
Phase I/II study of a short course of weekly cisplatin in patients with advanced solid tumoursA S Planting, M E van der Burg, M de Boer-Dennert, et al.
British Journal of Cancer|November 17, 2001
Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapyR de Wit, A C de Boer, G H vd Linden, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 26, 1999
Disposition of [G-(3)H]paclitaxel and cremophor EL in a patient with severely impaired renal functionH Gelderblom, J Verweij, E Brouwer, et al.
International Journal of Cancer|January 17, 1996
Modulation of immune parameters in patients with metastatic renal-cell cancer receiving combination immunotherapy (IL-2, IFN alpha and autologous IL-2-activated lymphocytes)J W Gratama, P I Schmitz, S H Goey, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|January 1, 1994
Utility assessment in cancer patients: adjustment of time tradeoff scores for the utility of life years and comparison with standard gamble scoresA M Stiggelbout, G M Kiebert, J Kievit, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1991
Phase I study of DABIS maleate given once every 3 weeksM E van der Burg, A S Planting, G Stoter, et al.
International Journal of Radiation Oncology, Biology, Physics|June 2, 1998
Expression of p53, p21/WAF/CIP, Bcl-2, Bax, Bcl-x, and Bak in radiation-induced apoptosis in testicular germ cell tumor linesH Burger, K Nooter, A W Boersma, et al.
Pageof 25